CVE-2021-24092

Microsoft Defender Elevation of Privilege Vulnerability

Description

Microsoft Defender Elevation of Privilege Vulnerability

Category

7.8
CVSS
Severity: High
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.58%
Vendor Advisory microsoft.com
Affected: Microsoft Microsoft Endpoint Protection
Affected: Microsoft Microsoft System Center Endpoint Protection
Affected: Microsoft Microsoft System Center 2012 R2 Endpoint Protection
Affected: Microsoft Microsoft Security Essentials
Affected: Microsoft Microsoft System Center 2012 Endpoint Protection
Affected: Microsoft Windows Defender
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2021-24092?
CVE-2021-24092 has been scored as a high severity vulnerability.
How to fix CVE-2021-24092?
To fix CVE-2021-24092, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2021-24092 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2021-24092 is being actively exploited. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2021-24092?
CVE-2021-24092 affects Microsoft Microsoft Endpoint Protection, Microsoft Microsoft System Center Endpoint Protection, Microsoft Microsoft System Center 2012 R2 Endpoint Protection, Microsoft Microsoft Security Essentials, Microsoft Microsoft System Center 2012 Endpoint Protection, Microsoft Windows Defender.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.